Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
85%
Cisplatin
46%
Chemotherapy
31%
Preoperative Chemotherapy
25%
Paclitaxel
21%
Early-stage Lung Cancer
21%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
20%
Phase I Study
17%
Phase II Trial
17%
Carboplatin
15%
Pemetrexed
14%
Dose Level
14%
Malignant Pleural Mesothelioma
13%
NCCN Guidelines
13%
Carboplatin-paclitaxel
13%
Median Survival
11%
Maximum Tolerated Dose
11%
Gross Total Resection
11%
Phase I Trial
11%
Brain Metastases
10%
Overall Survival
10%
Thoracic Irradiation
10%
Induction Chemotherapy
9%
Lung Cancer
9%
Partial Response
9%
Phase II Study
8%
Surgical Resection
8%
Gemcitabine
8%
Performance Status
8%
Randomized Trial
8%
Tumor
7%
Low-dose Cisplatin
7%
Antiemetics
7%
Confidence Interval
7%
Complete Response
7%
Response Rate
7%
Resectable Lung Cancer
7%
Ondansetron
7%
Randomized Phase III Trial
6%
Small Cell Lung Cancer
6%
Etoposide-cisplatin
6%
Gene Transfer
6%
Southwest Oncology Group
6%
Dyspnea
6%
Never-smokers
6%
National Comprehensive Cancer Network
6%
Etoposide
6%
Docetaxel
6%
Irradiation
6%
Vindesine
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
93%
Cisplatin
54%
Chemotherapy
52%
Paclitaxel
23%
Malignant Neoplasm
21%
Diseases
20%
Small Cell Lung Cancer
20%
Lung Cancer
19%
Phase II Trials
17%
Antiemetic Agent
17%
Carboplatin
14%
Etoposide
13%
Neoplasm
12%
Vomiting
11%
Overall Survival
11%
Pemetrexed
11%
Maximum Tolerated Dose
11%
Dexamethasone
11%
Protein P53
10%
Gefitinib
10%
Edatrexate
8%
Phase I Trials
8%
Neutropenia
7%
Serotonin Antagonist
7%
Solid Malignant Neoplasm
7%
Epidermal Growth Factor Receptor
6%
Zofran
6%
Pleura Mesothelioma
6%
Amifostine
6%
Gene Delivery
6%
Irinotecan
6%
Docetaxel
6%
Adenoviridae
6%
Survival Rate
6%
Vindesine
5%
Ifosfamide
5%
5 Chlorosulfaquinoxaline
5%
Topotecan
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Lung Cancer
41%
Cisplatin
27%
Surgery
26%
Diseases
25%
Radiation Therapy
22%
Preoperative Chemotherapy
19%
Malignant Neoplasm
17%
Overall Survival
16%
Oncology
16%
Neoplasm
15%
Induction Chemotherapy
13%
Carboplatin
12%
Paclitaxel
12%
Pleura Mesothelioma
10%
Protein P53
10%
Adjuvant Chemotherapy
9%
Non-Small Cell Lung Cancer
9%
Adjuvant Therapy
8%
Gene Transfer
7%
Cancer Staging
7%
Pneumonectomy
7%
Survival Rate
7%
Hazard Ratio
6%
Contusugene Ladenovec
6%
Neoadjuvant Chemotherapy
6%
Thymus Cancer
6%
Pemetrexed
6%
Gefitinib
6%
Adenoviridae
6%
Neoadjuvant Therapy
6%
Arm
6%
Recurrent Disease
6%
Metastatic Carcinoma
5%
Lung Tumor
5%
Mitomycin
5%
Long Term Survival
5%
Epidermal Growth Factor Receptor
5%
Intratumoral Drug Administration
5%
Chemoradiotherapy
5%